Sponsored Presentations

Organizations associated with the Joint Meeting as Exhibiting Companies and/or Sponsors are welcome to host Sponsored Presentations/Functions. All Sponsor Presentations/Functions must be preapproved by SPS Headquarters.

The fee for hosting such an event is $1,250 US, and includes the following: listing on the Joint Meeting website, listing in the final Program, and two premeeting email announcements distributed by SPS Headquarters.

If you have any questions please contact Laura Helm.

September 19, 2016


Room 7


Integrating Findings from Precedent Drug Approval Information into Drug Safety Assessment

Learn how leading pharmaceutical companies use precedent FDA and EMA drug approval information to help drive more informed drug safety assessments, drug candidate positioning and improve clinical trial designs, saving preclinical and clinical researchers significant time and costs. New FDA AERS (FAERS) search functionality will also be discussed, which helps researchers address new pharmacoepidemiology use cases. A complimentary breakfast will be available.

Room 16

Takara Bio USA, Inc. (formerly Clontech Laboratories, Inc.)

Human iPS Cell-Derived Cardiomyocytes Accurately Predict Cardiotoxic Effects of Reference Compounds for Utilization in Toxicity Screening Applications

Cellartis® Cardiomyocytes are a population of spontaneously beating cardiomyocytes derived from human induced pluripotent stem cells. These cardiomyocytes express cardiac-specific markers and are functionally similar to adult human cardiomyocytes, making them excellent in vitro tools for studies of human cardiomyocyte function and for cardiac safety pharmacology assays.



Room 7


Cardiac Safety/Tox Case Study: Chronic Drug Exposure Assessment Using Human iPSC-Derived Cardiomyocytes

Here we present a case study that compares both acute and chronic drug exposures in human iPS-derived cardiomyocytes (72 h impedence assay) to cardiac adverse events observed in anesthetized dogs. This screening strategy is currently employed in not only late preclinical safety studies but also prior to lead optimization.

Room 11

Cellular Dynamics International

Applying HTP Robotic Techniques to hiPSC-Cardiomyocyte Measurements: Rapid compounds and Beyond

Recent developments by Axion Biosystems and Cellular Dynamics International have coupled HTP robot-based cell handling with MEA recordings of hiPSC-derived cardiomyocytes. Come interact with the developers and industry users to hear how these advancements save time and money while producing robust and reproducible results with CiPA-compounds and more.

Room 16

Sophion Bioscience

Pioneering Ion Channels in Safety Pharmacology

Late Nav1.5 is an important target for safety pharmacology and until now no drug has reached clinical trials. A new modulator of late Nav1.5 has made it into clinical trials. Stable giga-seal recordings are critical for drug development. Here we show recordings of Nav subtypes obtained on QPatch and Qube384.



Room 7

Nanion Technologies Inc.

What’s New in CiPA: An Update of Stem Cell and Ion Channel Assays for Safety Studies

As a key member of the CiPA initiative, Nanion will give an update of the current status of the ion-channel and Myocyte Phase II studies, in which we are heavily involved. Join Sonja Stoelzle-Feix and other CiPA experts to gain an overview of this international collaboration. The workshop demonstrates the workflow of utilizing different platforms for the assessment of acute /chronic cardiotoxicity. We present results from reference compounds and drug-drug interactions tested on iPS-CMs. Furthermore, we evaluate a holistic approach for cardiac liabilities in accordance with CiPA guidelines. After the workshop, join us for an informal networking session!

Room 11

Data Sciences International

DSI’s 9th Annual Scientific Data Blast

Join us for an evening of education and entertainment at DSI’s 9th Annual Scientific Data Blast. Network and enjoy a cocktail while your colleagues present their latest scientific discoveries in an abbreviated format. Refreshments will be served.


September 20, 2016


Room 16

Charles River

How Comprehensive Do In Vitro Assays Have To Be To Predict Proarrhythmic Risk?

The comprehensive in vitro proarrhythmia assay (CiPA) aims to predict torsadogenic risk using cardiac ion channels, in silico modeling and stem-cellderived cardiomyocytes. These assays evaluate short-term exposure risks. Testing drugs for long-term effects on hERG current density and surface expression provides a more thorough estimation of proarrthythmic potential.



Room 7


Official product launch: easyTEL+ Large Animal Implantable Telemetry by emka TECHNOLOGIES

Presenting case studies using the emka TECHNOLOGIES’ easyTEL+ large animal implanted telemetry system. This powerful platform is cost effective, easy to use, and specifically designed for cardiovascular, cardiorespiratory, neurological studies. QTest Labs, WIL Research and PORSOLT scientists will present results from trials made at their facility.

Room 16

Data Sciences International

Combination Study Designs Drive Efficiency for Preclinical Research

Gaining more data per study is achievable through combination study designs. A panel of scientists will provide their perspectives on the advantages and challenges combining physiologic monitoring technologies to collect respiratory, cardiovascular and neurological endpoints from the same animal model. Lunch provided.



Room 7

ACEA Biosciences

Impact of Electrical Pacing on Cardiomyocyte Contractility and Its Implications for Safety

In this presentation using the xCELLigence® CardioECR System, we will show results demonstrating that iPSC-Cardiomyocytes display a negative forcefrequency relationship. Furthermore, using electrical pacing together with inhibitors of voltage-gated calcium channels or decreasing extracellular calcium concentrations, we discuss a protocol for assessment of positive and negative inotropic compounds.

Room 16

Clyde Biosciences LTD

Optical Sensors and Medium through-put Cardiotoxicological Assessment: Applications to Single Cells, 2D and 3D Systems

Commercially available induced pluripotent stem-cell derived cardiomyocytes are frequently use in 2D cultures for safety pharmacology to assess the potential of drugs to cause arrhythmias. The most common format is the 2D culture of cells in a monolayer. However, myocardium is an electrically coupled 3D syncytium, so the electrophysiological characteristics of a 3D structure may be a more appropriate format for cardiac safety tests. In this session, the baseline electrophysiology and the response to drugs of 3D iPSC-CM structures is compared with equivalent 2D monolayers. Differences are discussed in terms of underlying biophysics and relevance to intact human myocardium.

Exhibitor Information

Please visit the Exhibits Website to book your booth, view the exhibitor directory and more!